Furosemide stimulation of parathormone in humans: role of the calcium-sensing receptor and the renin-angiotensin system. by Muller, M.E. et al.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: Furosemide stimulation of parathormone in humans: role of the
calcium-sensing receptor and the renin-angiotensin system.
Authors: Muller ME, Forni Ogna V, Maillard M, Stoudmann C,
Zweiacker C, Anex C, Wuerzner G, Burnier M, Bonny O
Journal: Pflugers Archiv : European journal of physiology
Year: 2015 Dec
Issue: 467
Volume: 12
Pages: 2413-21
DOI: 10.1007/s00424-015-1714-4
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
  1 
 
Furosemide stimulation of parathormone in humans: 
Role of the calcium-sensing receptor and the renin-angiotensin 
system 
 
Marie-Eve Mullera*, Valentina Forni Ognaa*, Marc Maillarda, Candice Stoudmannb, Carole 
Zweiackera, Christiane Anexa, Grégoire Wuerznera, Michel Burniera* and Olivier Bonnyab*  
 
a Service of Nephrology, Department of Medicine, Centre Hospitalier Universitaire Vaudois, 
Lausanne, Switzerland 
b Department of Pharmacology and Toxicology, University of Lausanne, Lausanne, Switzerland 
 
* Equal contribution between first and last authors 
 
Short title: Mechanisms of furosemide-induced PTH secretion 
 
 
Word count manuscript: 6172 
Word count abstract: 223 
Total number of figures: 5 and 2 supplemental, Table: 1 
 
Key words: mineral metabolism; calcium sensing receptor; renin-angiotensin-aldosterone 
system; cinacalcet; furosemide 
 
Corresponding author:   
 Prof. Olivier Bonny  
 Service de néphrologie et consultation d’hypertension 
Centre Hospitalier Universitaire Vaudois, CHUV 
 Rue du Bugnon 17 
 1011 Lausanne-CHUV 
 E-mail address:        
 Olivier.Bonny@chuv.ch  
 
 
  
Mechanisms of furosemide-induced PTH secretion    2 
 
Abstract 
Interactions between sodium and calcium regulating systems are poorly characterized but 
clinically important. Parathyroid hormone (PTH) levels are increased shortly after furosemide 
treatment by an unknown mechanism and this effect is blunted by the previous administration of 
a calcimimetic in animal studies. Here, we explored further the possible underlying mechanisms 
of this observation in a randomized cross-over placebo-controlled study performed in 18 human 
males. Volunteers took either cinacalcet (60mg) or placebo and received a 20mg furosemide 
injection 3 hours later. Plasma samples were collected at 15 minutes intervals and analyzed for 
intact PTH, calcium, sodium, potassium, magnesium, phosphate, plasma renin activity (PRA) 
and aldosterone up to 6h after furosemide injection. Urinary electrolytes excretion was also 
monitored. Subjects under placebo presented a sharp increase in PTH levels after furosemide 
injection. In presence of cinacalcet, PTH levels were suppressed and marginal increase of PTH 
was observed. No significant changes in electrolytes and urinary excretion were identified that 
could explain the furosemide-induced increase in PTH levels. PRA and aldosterone were 
stimulated by furosemide injection, but were not affected by previous cinacalcet ingestion. 
Expression of NKCC1, but not NKCC2 was found in parathyroid tissue. In conclusion, our 
results indicate that furosemide acutely stimulates PTH secretion in absence of any detectable 
electrolyte changes in healthy adults. A possible direct effect of furosemide on parathyroid gland 
needs further studies. 
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Introduction 
Several experimental and clinical studies have reported that furosemide increases plasma 
parathyroid hormone (PTH) after acute or chronic furosemide treatment [6,10,18]. As of today, 
the precise mechanism whereby furosemide stimulates PTH remains largely unknown. 
Increased calciuria induced by furosemide has been proposed as a possible explanation for this 
phenomenon, but how calciuria can actually stimulate PTH secretion is obscure, as no 
significant change in serum calcium has been reported so far [6,27]. Thus, alternative 
mechanisms should be considered in order to explain the effect of furosemide on PTH 
secretion.  
If the mechanism remains unknown, furosemide-induced PTH secretion has well-recognized 
consequences which have been observed in animals and humans [13,24,30]. Indeed rats 
develop nephrocalcinosis only a few days after the beginning of a furosemide treatment [24] and 
chronic administration of furosemide has been associated with the development of 
nephrocalcinosis in neonates and infants [13,30]. Moreover, increasing evidence, in human 
adults, show that furosemide may also cause medullary nephrocalcinosis in a dose-dependent 
manner [17]. Interestingly, nephrocalcinosis did not occur in parathyroidectomized rats treated 
by furosemide in a preliminary study by Alon et al [25]. An indirect argument in favour of PTH 
implication in the nephrocalcinosis observed in furosemide-treated rats is the recent observation 
that simultaneous administration of furosemide and a calcimimetic blunts this effect [18]. Indeed, 
NPS R-467, a calcimimetic, is preventing nephrocalcinosis in young rats [25], further 
emphasizing the contribution of PTH rather than calciuria in inducing nephrocalcinosis after 
furosemide treatment. These recent findings also point to a possible role of the calcium-sensing 
receptor as a potential mediator of the effect of furosemide on PTH. Accordingly, we and others 
have reported that the administration of a calcimimetic to mice and rats decreases the activity of 
the renin-angiotensin system (RAS) and blunts the furosemide-induced increase of PTH and 
renin [18], suggesting that the renin-angiotensin-aldosterone might also be involved. As of 
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today, most of the observations made with calcimimetics have been done in animals and 
whether they occur similarly in humans has not been investigated. 
 
This randomized placebo-controlled cross-over study was designed to investigate the 
mechanisms mediating the acute effect of a single dose of furosemide on PTH in healthy adult 
males. In addition, we have assessed a possible interaction between cinacalcet, renin, 
aldosterone and PTH in response to furosemide. 
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Subjects and methods 
The study was conducted on healthy volunteers, recruited through advertisements in the 
Lausanne University Hospital and at the Lausanne University and Federal Polytechnical School 
sites. Informed consent was obtained from all individual participants included in the study. 
Eighteen Caucasian males aged 18 to 45 years, non-smokers and with no concomitant 
treatment were enrolled in the study.  To be included, they should have had, at the screening 
visit, a BMI >18 and < 25 Kg/m2,  normal clinical examination,  normal 12-leads ECG,  normal 
blood pressure (<140/90 mmHg) and  heart rate (HR) ≥ 45 and ≤ 90 beats/min after 5 minutes in 
supine position measured three times at 2-minute intervals on the left arm. Finally, the subjects 
had to be able to understand the written information and the written consent form and must 
have given written, dated and signed consent before starting any trial procedure. 
 
We excluded subjects with electrolyte disturbances, positive serology for HIV, HBV or HCV, 
positive detection of drugs in urine, any history of diseases or clinically significant conditions and 
drug therapy. 
 
All procedures performed were in accordance with the ethical standards of the institutional 
and/or national research committee and with the 1964 Helsinki declaration and its later 
amendments. The protocol was submitted and approved by the ethical committee of the Canton 
de Vaud, Switzerland and the Swiss drug authority "Swissmedic". The study was registered at 
ClinicalTrial.gov (ID NCT01519037).  
 
Study protocol 
The protocol included two similar 4-day periods with 3 days (D-3 to D-1) of run-in and 1 day of 
investigation (D0). According to the crossover design, subjects were randomly assigned to 
receive, in a blinded manner, either a single dose of 60 mg cinacalcet or placebo, orally, in the 
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first and second period respectively. From D-3 to D-1, the volunteers were asked to ingest a low 
salt diet in order to achieve a salt intake of < 3g/24h (50 mmol of Na+ per day). This was done to 
standardize salt intake and to stimulate the renin-angiotensin system. Compliance to the diet 
was verified using repeated 24h urine collections.  
The investigation day (D0) started at 07:45 with a brief clinical health check. Subjects were 
asked to empty their bladder and then a venous catheter was inserted in a forearm vein for 
repeated blood samplings. Participants remained in supine position for the whole day, except for 
voiding. Blood draw was always performed before voiding. Heart rate (HR) and blood pressure 
(BP) were measured every 30 minutes (every 15 min during the first hour after furosemide 
administration). A standardized hydration protocol (2 ml/kg of water every hour) was used all 
along the day.   
At 08.00 (H-3) participants received either placebo or 60 mg cinacalcet with a light breakfast. 
The medication was prepared by the hospital pharmacy and was blinded to both, investigators 
and subjects. Twenty mg of furosemide were injected intravenously immediately after the 11:00 
urine collection. BP and HR were measured every 15 minutes during one hour after iv 
furosemide injection. The following parameters were monitored in blood (every 15 min): sodium, 
potassium, total calcium, ionized calcium, albumin, magnesium, phosphate, and in urine (every 
15-30 min): sodium, potassium, total calcium, creatinine, uric acid, and urea. The samples were 
immediately processed, aliquoted and frozen. 
Thirteen subjects completed the protocol as indicated above (and are called furosemide positive 
(F+)). A second cluster of 5 participants following the same design was added afterwards 
without administration of furosemide in order to assess the spontaneous variations in PTH 
levels and are described as “furosemide negative (F-)“. According to the cross-over design of 
the study, four subgroups were analysed ie. the cinacalcet/furosemide positive (C/F+) and 
placebo/furosemide positive (P/F+) (n=13) and  cinacalcet/furosemide negative (C/F-) and 
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placebo/furosemide negative (P/F-) (n=5).  In the F+ group, 6 volunteers were assigned first to 
cinacalcet then to placebo. In the F- group, 3 participants received cinacalcet first.  
 
 
Laboratory analysis 
Urine and blood samples were measured at the Central Chemical Laboratory of the Lausanne 
University Hospital (CHUV, Lausanne, Vaud, Switzerland) using standard methods. 
Serum sodium (intra- and inter-batch CV: 0.20% and 0.90%, respectively), urine sodium (0.30% 
and 0.60%), serum potassium (0.20% and 0.90%) and urine potassium (0.40% and 0.90%) 
were measured by indirect potentiometry (Roche Diagnostics, Switzerland). Ionized calcium 
(0.80% and 0.60%) was measured by direct potentiometry (ABL 800, Radiometer Medical). 
Intact PTH was assessed by immunoassay (Immulite, Siemens). Plasma renin activity was 
measured by radioimmunoassay of generated concentration of angiotensin I using a 
commercial kit (RENCTK®; DiaSorin Inc., Stillwater, MN, USA). Measurement of aldosterone in 
the blood was performed with a commercial RIA (Coat-A-Count® Aldosterone kit, Siemens 
Medical Solutions Diagnostics; Los Angeles, CA, USA). 
 
Expression of NKCC1 and NKCC2 in parathyroid tissue 
Total mRNA was obtained from human parathyroid adenoma tissue (CR559081, OriGene, 
Rockville, MD, USA). One microgram of RNA was reverse-transcribed (PrimeScript RT reagent 
kit, Takara Bio Inc.) according to the manufacturer’s instructions. TaqMan Gene Expression 
Assays (Applied Biosystems) were used to detect NKCC1, NKCC2, PTH, PTHR1, and actin and 
quantitative real-time PCRs were carried out on an ABI PRISM 7500 equipment (Applied 
Biosystems, Carlsbad, CA) in triplicate for each sample, using TaqMan Universal PCR Master 
Mix (Applied Biosystems) in a final volume of 20µl. Results are expressed as relative values to 
actin and to PTH using the 2-ΔΔCT method. 
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Statistics 
Sample-size calculation 
Stata 12 (StataCorp LP, Texas, USA) was used prior to the study for power and sample-size 
calculation as well for the statistical analysis of the results. 
The hypothesis of this study was based on the assumption that the calcimimetic blunts the PTH 
response to furosemide. Thus the power of the study was calculated based on the changes in 
plasma PTH in the different groups. The increase in PTH levels after furosemide was assumed 
to have a normal distribution; the sample size calculation was therefore based on two-sample t-
test. Our hypothesis was an almost 2 fold basal change of PTH after furosemide in control 
group as observed in animals (i.e in term of absolute values of PTH an increase of 30 ng/l from 
30 to 60 ng/l). In the other group where the subjects were pre-treated with cinacalcet, basal PTH 
is assumed to be decrease by 80% compared to placebo and is expected to reach about 6 ng/l 
before furosemide stimulation and 12 ng/l after. Standard deviation of 75% of these increased 
values was used in the calculation. Based on these hypotheses with 12 evaluable subjects, the 
study has 90% power to detect a change of this magnitude at a 5% significance level (two-
sided). 
Analysis of the data revealed that there was neither sequence nor cross-over effect. There was 
no significant difference in baseline characteristics between participants beginning with 
cinacalcet and the others. 
 
Data are reported as mean ± SD or as median and interquartile range when appropriate. 
Comparisons between the different treatment groups were performed by analysis of the area 
under the curve and Wilcoxon rank test. A p-value less than 0.05 was considered significant.  
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Because the limit of quantification (LOQ) of iPTH at 3 ng/l was higher than levels measured in 
the majority of samples harvested in subjects treated with cinacalcet, the levels of iPTH in these 
latter samples were fixed at 1.5 ng/l for analysis, which is half of LOQ, a common strategy to 
replace censored data in distribution. This way to substitute censored data is rather 
conservative but also decreases variability. Therefore nonparametric tests were used to 
compare iPTH between groups. 
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Results 
Thirteen subjects received cinacalcet (C) or placebo (P) at baseline (H-3) and furosemide (F+) 3 
hours later at H0 (C/F+ and P/F+ groups), while 5 subjects followed the same protocol, but 
without receiving furosemide (P/F- and C/F- groups). There was no difference in term of age 
(27±5 vs 23±4 years), BMI (22.0±2.0 vs 21.8±1.7 kg/m2), systolic blood pressure (122±13 vs 
127±5 mmHg), diastolic blood pressure (70±8 vs 65±7 mmHg) and heart rate (66±12 vs 66±12 
bpm) at inclusion visit between the 13 volunteers subjected to furosemide injection and the 5 
individuals who did not receive furosemide. 
Baseline clinical characteristics of the subjects and the results of the baseline 24h urine 
collection are shown in Table 1. All values were within normal range and there was no 
significant difference between the groups except for serum creatinine which was slightly higher 
in the C/F- group, due to one subject who was slightly dehydrated. His creatinine reached 
normal values after rehydration. 
 
Changes in serum PTH levels for the four subgroups are illustrated over time on Figure 1. In 
the placebo group, a decrease in PTH was observed before the administration of furosemide in 
phase with the physiological diurnal variations of PTH [7]  from  (median; interquartile range, iqr) 
59.0 ng/l (52.0; 61.0) at H-3 to 20.0 ng/l (16.0;24.0) at H0 (p=0.002) in P/F+ subgroup and from 
63.0 (40.0;69.0) ng/l at H-3 to 25.0 (19.0; 35.0) ng/l at H0 (p=0.043) in P/F-subgroup. During the 
same time period, the administration of cinacalcet induced a rapid and marked decrease of 
serum PTH, which reached levels below the lower range limit in most of the subjects after three 
hours: from 37.0 (33.0 ; 42.0) ng/l at H-3 to 1.5 (1.5 ; 1.5) ng/l at H0 (p=0.002) in C/F+ subgroup 
and from 46.0 (35.0 ; 49.0) ng/l to 4.0 (1.5; 4.0) ng/l (p=0.043) in C/F- subgroup.  
 
The injection of furosemide produced a sharp increase in plasma PTH levels in subjects under 
placebo (P/F+) from (median; iqr) 20.0 (16.0; 24.0) ng/l at H0 to 38.0 (33.0; 48.0) ng/l at H1 
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(p=0.001). The furosemide effect on PTH persisted during three hours. In subjects pre-exposed 
to cinacalcet (C/F+ subgroup) the PTH response to furosemide did only change from 1.5 (1.5 ; 
1.5)  ng/l at H0 to  3.0 (1.5;1.9) ng/l at H1 (p=0.071), whereas no PTH change was observed in 
furosemide-naive subjects, passing from 4.0 (1.5; 4.0) ng/l at H0 to 5.0 (1.5; 7.0) ng/l at H1 
(p=0.17) in C/F- subgroup and from 25.0 (19.0; 35.0) ng/l at H0 to  28.0 (23.0; 37.0) ng/l at H1 
(p=0.06) in the P/F- subgroup. 
 
We measured the area under the curve (AUC) of plasma PTH between H0 and H6 in the four 
subgroups and found that subjects on placebo receiving furosemide showed significantly higher 
values as compared to other subgroups (Supplemental Figure S1): (mean±SD) 1248±404 
min*ng/l in P/F+ vs. 447 ±319 min*ng/l in C/F+ (p=0.003) and 320± 273 min*ng/l in P/F- 
(p=0.003 vs P/F +) and 452±363 min*ng/l in C/F- (p=0.007 vs P/F+). This further demonstrates 
that furosemide stimulates PTH secretion in humans and that this effect was not observed 
under cinacalcet. 
 
To decipher the mechanisms underlying the increase of PTH levels induced by furosemide, 
variations in serum ionized calcium and in urinary calcium excretion were measured (Figure 2).  
In the P/F+ group, no significant change in plasma ionized calcium was observed between 
baseline and the peak effect of furosemide (1.19 ±0.06 mmol/l at H0 and 1.19±0.03 mmol/l at 
H1; mean±SD).  In the C/F+ group, a decrease in plasma calcium was observed from 1.17±0.04 
at H0 to 1.15±0.04 mmol/l at H1 (p=0.008) (Figure 2A). No significant change in ionized calcium 
was seen in participants who did not receive furosemide (groups C/F- and P/F-). Taken together, 
these results strongly suggest that the change in PTH concentration observed in the P/F+ group 
cannot be attributed to variations of serum calcium. 
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Furosemide induced a significant increase in urinary calcium excretion which was similar under 
cinacalcet or placebo (Figure 2B). No change in calciuria was found in subjects who did not 
receive furosemide. There was no relevant difference between subjects under cinacalcet and 
placebo, when comparing the subgroups exposed to furosemide (P/F+ vs. C/F+, p=0.27) or 
between furosemide-naive subgroups (P/F- vs. C/F-, p= 0.50). 
 
Plasma sodium and potassium profiles were comparable between the groups during the whole 
investigation day (supplemental Figure S2). After furosemide injection, a slight but non-
significant decrease in serum potassium was observed with no change in plasma sodium. 
Plasma phosphate and magnesium showed comparable values between subgroups and were 
not influenced by cinacalcet or furosemide treatments (data not shown). 
 
Figure 3A and B summarizes changes in urinary sodium and potassium over time. As 
expected, furosemide induced a sharp increase of urinary sodium and potassium excretion both 
under placebo and cinacalcet.  
 
We further address the impact of cinacalcet and furosemide on plasma renin activity (PRA, 
Figure 4 panel A) and plasma aldosterone levels (Figure 4 panel B). Before the administration 
of furosemide a parallel decrease of the two parameters was observed, probably due to the 
variation of the hydration status and the known circadian variations of these hormones. 
In both P/F+ and C/F+ subgroups, furosemide induced a rapid and significant increase in 
plasma renin activity which peaked after 15 minutes.  
In furosemide naive groups no difference between placebo or cinacalcet-treated groups and no 
change in PRA was observed. As shown in Figure 4B, we have also investigated the changes in 
plasma aldosterone which followed a similar pattern as PRA. Again no significant difference was 
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found between P/F+ and C/F+, although in C/F+, plasma aldosterone levels tended to be lower 
at H0 and for the next 2 hours.  
Finally, we assessed whether parathyroid tissue expresses the furosemide-targeted transporters 
NKCC1 or NKCC2. Quantitative PCR was performed on reversed transcribed RNA obtained 
from parathyroid tissue of an excised adenoma. PTH was strongly expressed as expected, as 
well as PTH receptor (PTHR1) and NKCC1, while NKCC2 was not detected (Figure 5). 
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Discussion 
We showed here that an acute administration of the loop diuretic furosemide increases plasma 
PTH levels in healthy humans in absence of any measurable changes in serum ionized calcium 
or other plasma electrolytes. The PTH response to furosemide was blunted by the previous 
administration of the calcimimetic cinacalcet despite a slight decrease in plasma ionized calcium 
induced by cinacalcet. In contrast to animal studies, cinacalcet does not appear to blunt the 
stimulatory effect of furosemide on renin secretion. However, plasma aldosterone levels were 
lower after administration of cinacalcet. And the time course of PTH levels after furosemide 
correlated with the changes in PRA and aldosterone. Whether cinacalcet is mediating the effect 
of furosemide on PTH via renin-angiotensin-aldosterone system remains uncertain. At last, 
transient variations in plasma sodium and potassium do not appear to be associated with the 
change in PTH induced by furosemide. 
 
Several hypotheses have been proposed to explain furosemide-induced PTH secretion. (i) By 
increasing calciuria and slightly decreasing calcemia, furosemide could stimulate PTH secretion 
in the parathyroid gland [8]. (ii) Following furosemide injection, volume depletion and stimulation 
of the renin-angiotensin-aldosterone system could lead to increased PTH secretion by 
mechanisms not yet well understood [3,9,11]. (iii) Furosemide, by changing plasma potassium 
levels, could interfere with the Na+/K+-APTase activity, which is known to regulate PTH secretion 
in the parathyroid tissue [2]. (iv) Finally, furosemide could act directly on the parathyroid glands 
and stimulate PTH secretion. 
In previously published papers describing the ability of furosemide to stimulate PTH [28,10] the 
more simple hypothesis was that the increase in calciuria provoked by furosemide through its 
action on Henle's loop would lead to transient hypocalcemia which stimulates PTH release. In 
line with this hypothesis, Reichel et al found that in an anuric patient, furosemide had no effect 
on PTH [27]. In addition, the administration of hydrochlorothiazide, which reduces urinary 
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calcium excretion, was not associated with any change in PTH [31]. However, total as well as 
ionized plasma calcium levels remained unchanged after furosemide administration in these 
studies. A similar observation was made in our study in which we found a clear stimulation of 
PTH and hypercalciuria after furosemide treatment, but without any detectable change in serum 
ionized calcium. This suggests that calcemia may not be the link between calciuria and PTH 
release, unless very rapid and transient variations in calcemia occur and are under the detection 
threshold of our protocol. This could be the case if an immediate pool of calcium is mobilized 
from the bone, as suggested by some authors [26]. Against a prominent role of serum calcium 
stands our observation that in the cinacalcet group, PTH release after furosemide is blunted 
despite a rise in urinary calcium excretion and a decrease in plasma ionized calcium. The 
finding that a single dose of the calcimimetic cinacalcet given three hours before furosemide 
almost abolishes the PTH response to furosemide suggests that calcium sensing is, to some 
degree, involved in the response to furosemide but does not allow concluding on the precise 
role of calcium.  
 
We investigated the interaction between furosemide, PTH and the renin-angiotensin-
aldosterone system and evaluate the role of CaSR. Indeed, calcium sensing receptors are 
expressed in juxtaglomerular cells in mice [23] and rats [18].  Recent findings in humans 
indicate that there is a tight link between the RAAS and the parathyroid glands, suggesting that 
the RAAS may mediate the furosemide effect on PTH secretion [4,15,16,19,20,22,29]. In a 
previous experimental study, we demonstrated that administration of the calcimimetic RS568 
inhibited renin secretion in rats and blunted the renin response induced by furosemide [18]. The 
calcimimetic also blunted the PTH response to furosemide. For these reasons we have 
investigated the impact of cinacalcet on the renin response to furosemide and whether renin or 
aldosterone could be mediators of the furosemide effect on PTH release. In contrast to what 
was observed in the rat, cinacalcet did not inhibit the renin response to furosemide in our 
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healthy subjects. Of note however, a strong positive association between PTH and renin, as 
evidenced by the similar kinetic of the hormones along the study procedure was observed with 
an interesting synchronous course after furosemide injection. A similar synchrony was found 
between aldosterone and PTH, with a slight delay [9,3]. These observations could have led to 
the speculation of a possible implication of the RAAS in the furosemide-mediated PTH 
response. But, in calcimimetic receiving subjects, renin and aldosterone responses to 
furosemide were intact excluding renin and aldosterone as a mediator of the furosemide effect. 
Regarding the possible role of aldosterone the situation is however more complex. Indeed, 
plasma aldosterone levels were lower upon administration of cinacalcet and remained lower 
after the injection of furosemide. Whether the reduction in plasma aldosterone induced by 
cinacalcet has contributed to the blunting of PTH in the C/F+ group is thus possible but not 
ascertained by our data. 
 
Looking for other mechanisms mediating the furosemide increase in PTH, we explored the role 
of changes in serum electrolytes namely sodium, potassium, magnesium and phosphate. Brown 
et al have shown in vitro that hypokalemia and the exposure to ouabain, a specific inhibitor of 
the Na+-K+ ATPase, inhibited PTH secretion in isolated bovine parathyroid cells [1,2]. More 
recently, Imura [14] demonstrated the involvement of α-klotho in calcium-dependent trafficking 
of the Na+-K+ ATPase to the cell surface of the parathyroid gland's chief cells. These results 
suggest that the electrochemical gradient created by the klotho-dependent increase in cell 
surface expression of the Na+-K+ ATPase participates in the regulation of PTH secretion. This 
pathway is disrupted either in state of α-klotho deficiency or in case of ouabain exposure. Thus, 
hypokalemia may be associated with PTH secretion through the action of Na+-K+ ATPase. 
However, more recent data in rats questioned the regulating action of Na+-K+ ATPase on 
parathyroid activity [21]. In our study, no significant change in plasma sodium and magnesium 
were found, thus excluding a role of these electrolytes. A trend toward lower potassium levels 
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was noted, but was of similar magnitude between placebo- and cinacalcet-treated subjects, 
rejecting a major role of hypokalemia and of the Na+-K+ATPase in the increase of PTH. 
 
Finally, furosemide may act directly on the parathyroid gland tissue, given that sodium-
potassium-chloride co-transporters (NKCCs) are ubiquitously expressed. No evidence 
supporting this hypothesis has been provided so far, but we demonstrated here that the 
parathyroid tissue expresses NKCC1 mRNA, but not the kidney-specific gene NKCC2. This 
raises the possibility of a direct role of furosemide acting on the parathyroid gland, as previously 
shown for the juxtaglomerular apparatus by Castrop et al. [5]. NKCC1 has a Ki for furosemide in 
the micromolar range, compatible with plasma concentrations that can be rapidly reached after 
furosemide injection [12]. Further experiments testing this hypothesis need now to be 
conducted. 
 
Limitations of this study include the low number of volunteers, however reaching the calculated 
number for full power analysis, and the lack of measurement of 1,25 (OH)2-vitamin D. The fact 
that cinacalcet inhibited PTH to very low levels rendered the interpretation of the data more 
delicate, particularly with regard to PTH stimulation. However, we feel that even if cinacalcet 
significantly reduced PTH levels, the overall conclusions of the study are not affected. 
 
In conclusion, the furosemide-induced acute increase of PTH (doubling in less than 15 minutes) 
was ascertained in humans by this study. If the mechanism behind this observation remains 
unclear, we provide here insights in several working hypotheses. First, we did not observe 
changes in plasma calcium levels, excluding hypocalcemia as the main trigger for PTH 
increase. Second, we did not observe a clear correlation between the RAAS and PTH increase, 
suggesting only weak interaction between the two systems during furosemide stimulation in 
humans. Third, we did not identify any change in plasma electrolytes that could influence 
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Na+/K+-ATPase function involved in abnormal PTH secretion. Fourth, we show that human 
parathyroid tissue expresses the furosemide-target gene NKCC1, which may modulate PTH 
secretion. Finally, we showed that furosemide-induced PTH secretion is dependent upon 
calcium-sensing receptor function. This further emphasizes the role of CaSR at the interface 
between both calcium and sodium regulatory systems. 
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Figure legends 
 
Figure 1: Plasma iPTH profile according to subgroups during the investigation day. Plasma 
iPTH decreases in all groups but reaches below normal values in subjects under cinacalcet. 
Furosemide injection acutely stimulates PTH secretion in P/F+ subgroup. This effect is blunted 
in C/F+ subgroup. Furosemide was injected at time 0. Values are medians ± SEM. * p ≤ 0.01 for 
difference between time 0 (furosemide injection) and following time points.  All values between 
placebo and C/F+ are significantly different from time 0 to 6h using Wilcoxon signed rank test. 
Figure 2: Variations in plasma ionized calcium profile (panel A) and urine calcium profile (panel 
B) in the different subgroups during the investigation day. No significant change in ionized 
calcium values occurs in P/F+ subgroup, whereas a significant decrease is noted in C/F+ 
subgroup what suggests that PTH increase is not linked to plasma ionized calcium values. Both 
F+ groups show a significant acute increase in calciuria which does not occur in F- subgroups. 
P/F- placebo subgroup; C/F- cinacalcet subgroup; P/F+ placebo/furosemide subgroup; C/F+ 
cinacalcet/furosemide subgroup; Furosemide was injected at time 0. Values are means ± SEM. 
* p< 0.05 between P/F+ and P/F- subgroups. & p< 0.05 between C/F+ and C/F-. 
Figure 3: Urinary sodium (panel A), and urinary potassium excretions (panel B) in the various 
subgroups during the investigation day. All subjects show a similarly increased excretion of 
sodium and potassium after furosemide injection, whether there are under cinacalcet or 
placebo. Na+ = sodium; K+ = potassium. Furosemide was injected at time 0. Values are means ± 
SEM. 
All values between placebo and C/F+ are significantly different from time 0 to 1h using Wilcoxon 
signed rank test. Figure 4: Plasma Renin Activity (panel A) and plasma aldosterone (panel B) 
according to furosemide injected subgroups during the investigation day. In both subgroups, 
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Plasma Renin activity and plasma aldosterone values decrease in the first hours of the 
investigation days. However, Plasma Renin Activity increases significantly as soon as 15 
minutes after injection whereas it remains stable in furosemide naïve subgroups (not shown 
here for clarity reasons). Plasma aldosterone tends to a similar pattern but without reaching 
significantly different values. Furosemide was injected at time 0. Values are means ± SEM. 
*p<0.05 P/F+ vs. time at H0. &p< 0.05 between C/F+ vs. time at H0. 
Figure 5: NKCC1, but not NKCC2 mRNA is expressed in human parathyroid tissue. Messenger 
RNA was obtained from human parathyroid adenoma and NKCC1 and NKCC2 expression were 
assessed by quantitative PCR. NKCC2 was not detectable. PTH and PTHR1 served as controls 
and are strongly expressed. Expression is related to actin and to PTH expression. 
Supplemental Figure S1: Area under the curve (AUC) of plasma PTH in the different 
subgroups over time (H0 to H6). A significant difference is noted between the AUC of plasma 
PTH in furosemide injected subjects on placebo as compared to other subgroups. The 
significantly higher value indicates that stimulation of PTH secretion under furosemide does not 
occur under cinacalcet.  * denotes p< 0.05 compared to P/F+. 
Supplemental Figure S2: Plasma sodium (panel A) and potassium (panel B) over time. Values 
of plasma sodium and potassium remain stable in all subgroups during the whole investigation 
day, which denies a role of these electrolytes in plasma PTH secretion. Furosemide was 
injected at time 0. Values are means ± SEM  
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Table 1. Baseline characteristics of participants at the beginning of each investigation day of the 
cross-over design. iPTH = intact parathyroid hormone; PRA=plasma renin activity¸ Na+= Sodium 
K+=potassium, Ca++=calcium 
 
   
With furosemide  
(N=13)  
Without furosemide  
(N=5)  
Cinacalcet 
 
Placebo 
 P 
Cinacalcet 
 
Placebo 
 P 
Serum 
iPTH (ng/l) 38.0±12.0 42.7±15.5 NS 51.2±19.9 55.4±23.0 NS 
PRA (ng/ml/h)) 1.73±1.20 2.60±1.68 NS 2.66±1.50 2.80±1.09 NS 
Aldosterone 
(pg/ml) 482±252 454±243 NS 434±271 492±221 NS 
Plasma 
Creatinine 
(µmol/l) 87.2±7.4 88.4±9.9 NS 94.2±12.9 88.0±10.8 0.01 
Albumin (g/l) 47.7±3.2 47.5±2.6 NS 48.8±1.5 49.6±1.3 NS 
Na+ (mmol/l) 140±1 140±1 NS 141±1.2 140±1 NS 
K+ (mmol/l) 3.8±0.3 3.9±0.2 NS 3.9±0.5 4.1±0.3 NS 
Ca total 
(mmol/l) 2.3±0.1 2.3±0.1 NS 2.3±0.1 2.3±0.1 NS 
Ca++ ionized 
(mmol/l) 
1.1±0.1 1.2±0.1 NS 1.1±0.1 1.2±0.1 NS 
Ca corrected 
(mmol/l) 2.2±0.1 2.2±0.1 NS 2.2±0.08 2.2±0.1 NS 
Phosphate 
(mmol/l) 1.2±0.1 1.2±0.1 NS 1.3±0.2 1.3±0.2 NS 
24 hour urine 
Creatinine 
(µmol/d) 
13’432± 
3’183 
13’835± 
3’752 NS 
14,655± 
2043 
15’374± 
3’210 NS 
Na+ 
(mmol/d) 
52.8±29.6 59.4±43.6 NS 31.4±18.3 40.1±20.9 NS 
K+ (mmol/d) 72.8±28.2 84.7±29.2 NS 72.0±20.8 40.6±23.0 NS 
Ca++ 
(mmol/d) 
1.5±1.3 1.2±0.9 NS 0.2±0.1 8.7±11.0 NS 
Phosphate 
(mmol/d) 36.0±18.0 34.1±16.2 NS 40.1±8.5 31.2±10.3 NS 
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